Oflovir (Ofloxacin)

Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription and repair. By blocking these targets, the drug prevents bacterial cells from reproducing and leads to rapid bactericidal activity against susceptible organisms.

The dosage of Oflovir is determined by the treating physician based on the specific infection, patient age, renal function and other clinical factors. Prescribers select the appropriate strength, frequency and duration according to approved guidelines.

Ofloxacin is classified as a pregnancy‑category C drug; it should only be used when the potential benefit outweighs the risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Oflovir product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ofloxacin offers a broad spectrum of activity similar to other fluoroquinolones such as ciprofloxacin and levofloxacin, but its pharmacokinetic profile provides good tissue penetration and a convenient dosing schedule for many infections. Choice among agents depends on local resistance patterns, patient tolerance and specific infection site.

Oflovir tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Oflovir is supplied as oral tablets that are taken by mouth with or without food, unless otherwise directed by a healthcare professional. The tablet should be swallowed whole with an adequate amount of water; crushing or chewing may affect absorption.

The most serious adverse effects include tendon rupture or tendinitis, QT‑interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they experience sudden tendon pain, palpitations, severe rash or persistent diarrhea.

Oflovir is contraindicated in individuals with a known hypersensitivity to ofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, and in those with established prolonged QT interval unless benefits clearly outweigh risks.